Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.
AffiliationDepartment of Clinical Pharmacology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, England.
MetadataShow full item record
AbstractCyclophosphamide (CP) was administered to eight patients with metastatic bronchial carcinoma in escalating doses of 1.5, 2.5, and 3.5 g/m2 at intervals of 3 weeks. The proportion of the administered dose converted into alkylating metabolites was similar for each dose and there was no evidence to suggest that the enzyme system responsible for activating CP was saturated even with the highest dose. Considerable between-patient variation in drug metabolism was observed, but within each patient the fraction metabolised remained constant.
CitationPharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. 1983, 11 (3):196-9 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- I.v. melphalan in carcinoma of the lung: effect of cyclophosphamide priming on hematopoietic toxicity.
- Authors: Spitzer G, Valdivieso M, Farha P, Murphy WK, Dhingra HM, Chiuten D, Umsawasdi T, Holoye P
- Issue date: 1986 Apr
- Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide.
- Authors: Bonomi P, O'Reilly W, Vogl SE, Ruckdeschel JC, Stolbach L, Bunting N, Creech RH
- Issue date: 1985 Sep
- Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
- Authors: Curtis JE
- Issue date: 1974 Nov-Dec
- Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
- Authors: Johnson DH, Wolff SN, Hainsworth JD, Porter LL, Grosh WW, Hande KR, Greco FA
- Issue date: 1985 Feb
- The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
- Authors: McNiel NO, Morgan LR Jr
- Issue date: 1981 Nov